Neurotrophins as regulators of urinary bladder function

Nature Reviews Urology

Volumn 9, Issue 11, 2012, Pages 628-637

  Ochodnicky, Peter ^a   Cruz, Célia D ^b   Yoshimura, Naoki ^c   Cruz, Francisco ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF PORTO   (Portugal)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; NERVE GROWTH FACTOR; NEUROTROPHIN; NEUROTROPHIN 3; NEUROTROPHIN 4;

BLADDER FILLING; BLADDER FUNCTION; CENTRAL NERVOUS SYSTEM; DIAGNOSTIC ACCURACY; EVIDENCE BASED PRACTICE; HUMAN; MICTURITION; NERVE CELL PLASTICITY; NOCICEPTION; OVERACTIVE BLADDER; PERIPHERAL NERVOUS SYSTEM; PRIORITY JOURNAL; REVIEW; SOMATOSENSORY SYSTEM; URINARY FREQUENCY; URINARY URGENCY; BLADDER; CYSTITIS, INTERSTITIAL; LOWER URINARY TRACT SYMPTOM; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; URINARY BLADDER, OVERACTIVE; URINE;

BIOMARKERS; CYSTITIS, INTERSTITIAL; HUMANS; LOWER URINARY TRACT SYMPTOMS; NERVE GROWTH FACTORS; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINATION;

EID: 84869089923     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2012.178     Document Type: Review

References (113)

1. Fowler, C. J., Griffiths, D. & de Groat, W. C. The neural control of micturition. Nat. Rev. Neurosci. 9, 453-466 (2008). (Pubitemid 351704950)
2. Hashim, H. & Abrams, P. Overactive bladder: an update. Curr. Opin. Urol. 17, 231-236 (2007). (Pubitemid 46905193)
3. Abrams, P. et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61, 37-49 (2003). (Pubitemid 36151708)
4. de Groat, W. C. & Yoshimura, N. Afferent nerve regulation of bladder function in health and disease. Handb. Exp. Pharmacol. 194, 91-138 (2009).
5. Kanai, A. & Andersson, K. E. Bladder afferent signaling: recent findings. J. Urol. 183, 1288-1295 (2010).
6. Fall, M., Oberpenning, F. & Peeker, R. Treatment of bladder pain syndrome/interstitial cystitis can we make evidence-based decisions? Eur. Urol. 54, 65-75 (2008).
7. Hanno, P. et al. Bladder Pain Syndrome Committee of the International Consultation on Incontinence. Neurourol. Urodyn. 29, 191-198 (2010).
8. Wiseman, O. J. et al. The ultrastructure of bladder lamina propria nerves in healthy subjects and patients with detrusor hyperreflexia. J. Urol. 168, 2040-2045 (2002).
9. Apodaca, G., Balestreire, E. & Birder, L. A. The uroepithelial- associated sensory web. Kidney Int. 72, 1057-1064 (2007). (Pubitemid 47609034)
10. Birder, L. A. & de Groat, W. C. Mechanisms of disease: involvement of the urothelium in bladder dysfunction. Nat. Clin. Pract. Urol. 4, 46-54 (2007). (Pubitemid 46062986)
11. Pezet, S. & McMahon, S. B. Neurotrophins: mediators and modulators of pain. Ann. Rev. Neurosci. 29, 507-538 (2006). (Pubitemid 44476854)
12. Andersson, K. E. Detrusor myocyte activity and afferent signaling. Neurourol. Urodyn. 29, 97-106 (2010).
13. Gillespie, J. I., van Koeveringe, G. A., de Wachter, S. G. & de Vente, J. On the origins of the sensory output from the bladder: the concept of afferent noise. BJU Int. 103, 1324-1333 (2009).
14. Kawakami, T., Wakabayashi, Y., Isono, T., Aimi, Y. & Okada, Y. Expression of neurotrophin messenger RNAs during rat urinary bladder development. Neurosci. Lett. 329, 77-80 (2002).
15. Vizzard, M. A., Wu, K. H. & Jewett, I. T. Developmental expression of urinary bladder neurotrophic factor mRNA and protein in the neonatal rat. Brain Res. Dev. Brain Res. 119, 217-224 (2000). (Pubitemid 30089812)
16. Levi-Montalcini, R. & Hamburger, V. Selective growth stimulating effects of mouse sarcoma on the sensory and sympathetic nervous system of the chick embryo. J. Exp. Zool. 116, 321-361 (1951).
17. Levi-Montalcini, R. The nerve growth factor 35 years later. Science 237, 1154-1162 (1987). (Pubitemid 17124912)
18. Ernsberger, U. Role of neurotrophin signalling in the differentiation of neurons from dorsal root ganglia and sympathetic ganglia. Cell Tissue Res. 336, 349-384 (2009).
19. Tuttle, J. B. & Steers, W. D. Nerve growth factor responsiveness of cultured major pelvic ganglion neurons from the adult rat. Brain Res. 588, 29-40 (1992).
20. Schnegelsberg, B. et al. Overexpression of NGF in mouse urothelium leads to neuronal hyperinnervation, pelvic sensitivity, and changes in urinary bladder function. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R534-R547 (2010).
21. Skaper, S. D., Pollock, M. & Facci, L. Mast cells differentially express and release active high molecular weight neurotrophins. Brain Res. Mol. Brain Res. 97, 177-185 (2001). (Pubitemid 34025096)
22. Skaper, S. D. Nerve growth factor: a neurokine orchestrating neuroimmune-endocrine functions. Mol. Neurobiol. 24, 183-199 (2001). (Pubitemid 34066685)
23. Jang, J., Park, E. Y., Seo, S. I., Hwang, T. K. & Kim, J. C. Effects of intravesical instillation of cyclooxygenase-2 inhibitor on the expression of inducible nitric oxide synthase and nerve growth factor in cyclophosphamide- induced overactive bladder. BJU Int. 98, 435-439 (2006).
24. Gonzalez, R. R. et al. Modulating bladder neuro-inflammation: RDP58, a novel anti-inflammatory peptide, decreases inflammation and nerve growth factor production in experimental cystitis. J. Urol. 173, 630-634 (2005).
25. Meyer-Siegler, K. L. & Vera, P. L. Substance P induced release of macrophage migration inhibitory factor from rat bladder epithelium. J. Urol. 171, 1698-1703 (2004). (Pubitemid 38365467)
26. Dupont, M. C., Spitsbergen, J. M., Kim, K. B., Tuttle, J. B. & Steers, W. D. Histological and neurotrophic changes triggered by varying models of bladder inflammation. J. Urol. 166, 1111-1118 (2001). (Pubitemid 32751054)
27. Mantyh, P. W., Koltzenburg, M., Mendell, L. M., Tive, L. & Shelton, D. L. Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology 115, 189-204 (2011).
28. Apfel, S. C. et al. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy: a randomized controlled trial. rhNGF Clinical Investigator Group. JAMA 284, 2215-2221 (2000).
29. Thoenen, H. & Sendtner, M. Neurotrophins: from enthusiastic expectations through sobering experiences to rational therapeutic approaches. Nat. Neurosci. 5, 1046-1050 (2002). (Pubitemid 35247196)
30. Steers, W. D. & Tuttle, J. B. Mechanisms of Disease: the role of nerve growth factor in the pathophysiology of bladder disorders. Nat. Clin. Pract. Urol. 3, 101-110 (2006). (Pubitemid 43239267)
31. Dmitrieva, N. & McMahon, S. B. Sensitisation of visceral afferents by nerve growth factor in the adult rat. Pain 66, 87-97 (1996). (Pubitemid 26247028)
32. Dmitrieva, N., Shelton, D., Rice, A. S. & McMahon, S. B. The role of nerve growth factor in a model of visceral inflammation. Neuroscience 78, 449-459 (1997). (Pubitemid 27170336)
33. Zvara, P. & Vizzard, M. A. Exogenous overexpression of nerve growth factor in the urinary bladder produces bladder overactivity and altered micturition circuitry in the lumbosacral spinal cord. BMC Physiol. 7, 9 (2007).
34. Yoshimura, N. et al. Bladder overactivity and hyperexcitability of bladder afferent neurons after intrathecal delivery of nerve growth factor in rats. J. Neurosci. 26, 10847-10855 (2006).
35. Frias, B. et al. TRPV1 mediates NGF-induced bladder overactivity and noxious input. BJU Int. http://dx.doi.org/10.1111/j.1464-410X.2012.11187.x
36. Winston, J., Toma, H., Shenoy, M. & Pasricha, P. J. Nerve growth factor regulates VR-1 mRNA levels in cultures of adult dorsal root ganglion neurons. Pain 89, 181-186 (2001). (Pubitemid 32146397)
37. Zhuang, Z. Y., Xu, H., Clapham, D. E. & Ji, R. R. Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J. Neurosci. 24, 8300-8309 (2004). (Pubitemid 39280809)
38. Charrua, A. et al. Functional transient receptor potential vanilloid 1 is expressed in human urothelial cells. J. Urol. 182, 2944-2950 (2009).
39. Snider, W. D. Functions of the neurotrophins during nervous system development: what the knockouts are teaching us. Cell 77, 627-638 (1994). (Pubitemid 24175600)
40. Song, X. Y., Li, F., Zhang, F. H., Zhong, J. H. & Zhou, X. F. Peripherally-derived BDNF promotes regeneration of ascending sensory neurons after spinal cord injury. PLoS ONE 3, e1707 (2008).
41. Girard, B. M., Malley, S. E. & Vizzard, M. A. Neurotrophin/receptor expression in urinary bladder of mice with overexpression of NGF in urothelium. Am. J. Physiol. Renal Physiol. 300, F345-F355 (2011).
42. Pinto, R. et al. Sequestration of brain derived nerve factor by intravenous delivery of TrkB-Ig2 reduces bladder overactivity and noxious input in animals with chronic cystitis. Neuroscience 166, 907-916 (2010).
43. Vizzard, M. A. Changes in urinary bladder neurotrophic factor mRNA and NGF protein following urinary bladder dysfunction. Exp. Neurol. 161, 273-284 (2000). (Pubitemid 30136549)
44. Pezet, S., Malcangio, M. & McMahon, S. B. BDNF: a neuromodulator in nociceptive pathways? Brain Res. Rev. 40, 240-249 (2002). (Pubitemid 36183173)
45. Michael, G. J. et al. Nerve growth factor treatment increases brain-derived neurotrophic factor selectively in TrkA-expressing dorsal root ganglion cells and in their central terminations within the spinal cord. J. Neurosci. 17, 8476-8490 (1997). (Pubitemid 27461069)
46. Moutzouris, D. A. & Falagas, M. E. Interstitial cystitis: an unsolved enigma. Clin. J. Am. Soc. Nephrol. 4, 1844-1857 (2009).
47. Hanno, P. M. et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J. Urol. 185, 2162-2170 (2011).
48. Berry, S. H. et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J. Urol. 186, 540-544 (2011).
49. Liu, H. T. & Kuo, H. C. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology 70, 463-468 (2007).
50. Pinto, R. et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur. Urol. 58, 360-365 (2010).
51. Christmas, T. J., Rode, J., Chapple, C. R., Milroy, E. J. & Turner-Warwick, R. T. Nerve fibre proliferation in interstitial cystitis. Virchows Arch. A Pathol. Anat. Histopathol. 416, 447-451 (1990). (Pubitemid 20099790)
52. Christmas, T. J. & Rode, J. Characteristics of mast cells in normal bladder, bacterial cystitis and interstitial cystitis. Br. J. Urol. 68, 473-478 (1991).
53. Birder, L. A., Hanna-Mitchell, A. T., Mayer, E. & Buffington, C. A. Cystitis, co-morbid disorders and associated epithelial dysfunction. Neurourol. Urodyn. 30, 668-672 (2011).
54. Chai, T. C. & Keay, S. New theories in interstitial cystitis. Nat. Clin. Pract. Urol. 1, 85-89 (2004). (Pubitemid 40823733)
55. Lowe, E. M. et al. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br. J. Urol. 79, 572-577 (1997). (Pubitemid 28321098)
56. Chancellor, M. B. et al. Drug Insight: biological effects of botulinum toxin A in the lower urinary tract. Nat. Clin. Pract. Urol. 5, 319-328 (2008). (Pubitemid 351818884)
57. Liu, H. T., Tyagi, P., Chancellor, M. B. & Kuo, H. C. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int. 104, 1476-1481 (2009).
58. Pinto, R. et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. Eur. Urol. 58, 360-365 (2010).
59. Tyagi, P. et al. Intravesical antisense therapy for cystitis using TAT-peptide nucleic acid conjugates. Mol. Pharm. 3, 398-406 (2006). (Pubitemid 44351922)
60. Frias, B. et al. Intrathecal blockade of Trk receptor and neurotrophins sequestration reduces pain and urinary frequency in an animal model of chronic bladder inflammation. Neurourol. Urodyn. 28, 708 (2009).
61. Hu, V. Y. et al. Decrease in bladder overactivity with REN1820 in rats with cyclophosphamide induced cystitis. J. Urol. 173, 1016-1021 (2005). (Pubitemid 40239387)
62. Evans, R. J. et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J. Urol. 185, 1716-1721 (2011).
63. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00999518?term=tanezumab&rank=16 (2011).
64. Wood, J. N. Nerve growth factor and pain. N. Engl. J. Med. 363, 1572-1573 (2010).
65. de Groat, W. C. & Yoshimura, N. Plasticity in reflex pathways to the lower urinary tract following spinal cord injury. Exp. Neurol. 235, 123-132 (2012).
66. Kalsi, V. & Fowler, C. J. Therapy Insight: bladder dysfunction associated with multiple sclerosis. Nat. Clin. Pract. Urol. 2, 492-501 (2005). (Pubitemid 41594403)
67. Apostolidis, A. et al. Decreased sensory receptors P2X3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. J. Urol. 174, 977-982 (2005). (Pubitemid 41140654)
68. Liu, H. T., Chancellor, M. B. & Kuo, H. C. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur. Urol. 56, 700-706 (2009).
69. Giannantoni, A. et al. Botulinum-A toxin injections into the detrusor muscle decrease nerve growth factor bladder tissue levels in patients with neurogenic detrusor overactivity. J. Urol. 175, 2341-2344 (2006). (Pubitemid 43668538)
70. Zvarova, K., Murray, E. & Vizzard, M. A. Changes in galanin immunoreactivity in rat lumbosacral spinal cord and dorsal root ganglia after spinal cord injury. J. Comp. Neurol. 475, 590-603 (2004). (Pubitemid 38859368)
71. Persson, K., Steers, W. D. & Tuttle, J. B. Regulation of nerve growth factor secretion in smooth muscle cells cultured from rat bladder body, base and urethra. J. Urol. 157, 2000-2006 (1997). (Pubitemid 27171828)
72. Tanner, R., Chambers, P., Khadra, M. H. & Gillespie, J. I. The production of nerve growth factor by human bladder smooth muscle cells in vivo and in vitro. BJU Int. 85, 1115-1119 (2000). (Pubitemid 30348811)
73. Ramer, M. S., Bradbury, E. J. & McMahon, S. B. Nerve growth factor induces P2X(3) expression in sensory neurons. J. Neurochem. 77, 864-875 (2001). (Pubitemid 32466783)
74. Seki, S. et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J. Urol. 168, 2269-2274 (2002).
75. Seki, S. et al. Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. J. Urol. 171, 478-482 (2004). (Pubitemid 37549215)
76. Mirone, V., Imbimbo, C., Longo, N. & Fusco, F. The detrusor muscle: an innocent victim of bladder outlet obstruction. Eur. Urol. 51, 57-66 (2007). (Pubitemid 44821527)
77. Steers, W. D., Kolbeck, S., Creedon, D. & Tuttle, J. B. Nerve growth factor in the urinary bladder of the adult regulates neuronal form and function. J. Clin. Invest. 88, 1709-1715 (1991).
78. Steers, W. D., Creedon, D. J. & Tuttle, J. B. Immunity to nerve growth factor prevents afferent plasticity following urinary bladder hypertrophy. J. Urol. 155, 379-385 (1996). (Pubitemid 126426498)
79. Liu, H. T. & Kuo, H. C. Urinary nerve growth factor levels are increased in patients with bladder outlet obstruction with overactive bladder symptoms and reduced after successful medical treatment. Urology 72, 104-108 (2008).
80. Kim, J. C. et al. Changes of urinary nerve growth factor and prostaglandins in male patients with overactive bladder symptom. Int. J. Urol. 12, 875-880 (2005). (Pubitemid 41726958)
81. Yokoyama, T., Kumon, H. & Nagai, A. Correlation of urinary nerve growth factor level with pathogenesis of overactive bladder. Neurourol. Urodyn. 27, 417-420 (2008). (Pubitemid 351991207)
82. Kim, J. C., Kim, D. B., Seo, S. I., Park, Y. H. & Hwang, T. K. Nerve growth factor and vanilloid receptor expression, and detrusor instability, after relieving bladder outlet obstruction in rats. BJU Int. 94, 915-918 (2004). (Pubitemid 39472496)
83. Persson, K., Sando, J. J., Tuttle, J. B. & Steers, W. D. Protein kinase C in cyclic stretch-induced nerve growth factor production by urinary tract smooth muscle cells. Am. J. Physiol. 269, C1018-C1024 (1995).
84. Araki, I. et al. Overexpression of epithelial sodium channels in epithelium of human urinary bladder with outlet obstruction. Urology 64, 1255-1260 (2004). (Pubitemid 39647085)
85. Kim, J. C., Park, E. Y., Seo, S. I., Park, Y. H. & Hwang, T. K. Nerve growth factor and prostaglandins in the urine of female patients with overactive bladder. J. Urol. 175, 1773-1776 (2006).
86. Liu, H. T. & Kuo, H. C. Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol. Urodyn. 28, 78-81 (2009).
87. Liu, H. T. & Kuo, H. C. Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J. Urol. 179, 2270-2274 (2008).
88. Birder, L. A., Wolf-Johnston, A., Griffiths, D. & Resnick, N. M. Role of urothelial nerve growth factor in human bladder function. Neurourol. Urodyn. 26, 405-409 (2007). (Pubitemid 46717590)
89. Liu, H. T., Lin, H. & Kuo, H. C. Increased serum nerve growth factor levels in patients with overactive bladder syndrome refractory to antimuscarinic therapy. Neurourol. Urodyn. 30, 1525-1529 (2011).
90. Liu, H. T., Chancellor, M. B. & Kuo, H. C. Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int. 103, 1668-1672 (2009).
91. Kuo, H. C., Liu, H. T. & Chancellor, M. B. Urinary nerve growth factor is a better biomarker than detrusor wall thickness for the assessment of overactive bladder with incontinence. Neurourol. Urodyn. 29, 482-487 (2010).
92. Kebapci, N., Yenilmez, A., Efe, B., Entok, E. & Demirustu, C. Bladder dysfunction in type 2 diabetic patients. Neurourol. Urodyn. 26, 814-819 (2007). (Pubitemid 47548248)
93. Lee, W. C., Wu, H. P., Tai, T. Y., Yu, H. J. & Chiang, P. H. Investigation of urodynamic characteristics and bladder sensory function in the early stages of diabetic bladder dysfunction in women with type 2 diabetes. J. Urol. 181, 198-203 (2009).
94. Daneshgari, F., Liu, G., Birder, L., Hanna-Mitchell, A. T. & Chacko, S. Diabetic bladder dysfunction: current translational knowledge. J. Urol. 182, S18-S26 (2009).
95. Steinbacher, B. C. Jr & Nadelhaft, I. Increased levels of nerve growth factor in the urinary bladder and hypertrophy of dorsal root ganglion neurons in the diabetic rat. Brain Res. 782, 255-260 (1998). (Pubitemid 28123002)
96. Sasaki, K. et al. Diabetic cystopathy correlates with a long-term decrease in nerve growth factor levels in the bladder and lumbosacral dorsal root ganglia. J. Urol. 168, 1259-1264 (2002).
97. Tomlinson, D. R., Fernyhough, P. & Diemel, L. T. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factors. Diabetes 46, S43-S49 (1997). (Pubitemid 27377397)
98. Anand, P. et al. The role of endogenous nerve growth factor in human diabetic neuropathy. Nat. Med. 2, 703-707 (1996). (Pubitemid 26191962)
99. Sasaki, K. et al. Gene therapy using replication-defective herpes simplex virus vectors expressing nerve growth factor in a rat model of diabetic cystopathy. Diabetes 53, 2723-2730 (2004). (Pubitemid 39299286)
100. Liu, H. T., Chancellor, M. B. & Kuo, H. C. Urinary nerve growth factor level could be a biomarker in the differential diagnosis of miXed urinary incontinence in women. BJU Int. 102, 1440-1444 (2008).
101. Kuo, H. C., Liu, H. T. & Chancellor, M. B. Can urinary nerve growth factor be a biomarker for overactive bladder? Rev. Urol. 12, e69-e77 (2010).
102. Antunes-Lopes, T., Carvalho-Barros, S., Cruz, C. D., Cruz, F. & Martins-Silva, C. Biomarkers in overactive bladder: a new objective and noninvasive tool? Adv. Urol. 382431 (2011).
103. Antunes-Lopes, T. et al. Urinary levels of brain derived neurotrophic factor (BDNF) in women with overactive bladder (OAB) syndrome correlate with the severity of symptoms. Eur. Urol. 10, 277-278 (2011).
104. Okragly, A. J. et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J. Urol. 161, 438-441 (1999).
105. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT01060254 (2011).
106. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00929188 (2012).
107. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/ct2/show/NCT00944892 (2011).
108. Lane, N. E. et al. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363, 1521-1531 (2010).
109. Holmes, D. Anti-NGF painkillers back on track? Nat. Rev. Drug Discov. 11, 337-338 (2012).
110. Apostolidis, A. et al. Recommendations on the use of botulinum toXin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report. Eur. Urol. 55, 100-119 (2009).
111. Chuang, Y. C., Lee, W. C., Lee, W. C. & Chiang, P. H. Intravesical liposome versus oral pentosan polysulfate for interstitial cystitis/painful bladder syndrome. J. Urol. 182, 1393-1400 (2009).
112. Eibl, J. K., Chapelsky, S. A. & Ross, G. M. Multipotent neurotrophin antagonist targets brain-derived neurotrophic factor and nerve growth factor. J. Pharmacol. Exp. Ther. 332, 446-454 (2010).
113. Hefti, F. F. et al. Novel class of pain drugs based on antagonism of, N. G. F. Trends Pharmacol. Sci. 27, 85-91 (2006). (Pubitemid 43184029)